Edgewise Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2022 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Edgewise Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q3 2024.
  • Edgewise Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 4.51 %, a 26.2% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 4.51 -1.6 -26.2% Sep 30, 2024
Q2 2024 4.97 -0.44 -8.14% Jun 30, 2024
Q1 2024 5.51 +0.46 +9.12% Mar 31, 2024
Q4 2023 6.31 +1.41 +28.8% Dec 31, 2023
Q3 2023 6.11 +1.73 +39.5% Sep 30, 2023
Q2 2023 5.4 +1.34 +33% Jun 30, 2023
Q1 2023 5.04 Mar 31, 2023
Q4 2022 4.9 Dec 31, 2022
Q3 2022 4.38 Sep 30, 2022
Q2 2022 4.06 Jun 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.